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Experiment Hypothesis
The combined effect of anti-resorptive drugs plus in-flight exercise 
regimen will attenuate space flight induced loss in bone mass and 
strength and reduce renal stone risk.
Experiment Status
• To date 7 out of 10 subjects are enrolled -- all taking alendronate  
• 4 crewmembers have completed ISS long duration missions without 
incident and will be reported here
• 3 additional crewmembers are scheduled to complete the flight      
portion of the protocol this year
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Experiment Measurements
Bone Loss
• PRIMARY ENDPOINT:  Hip trabecular BMD  by QCT
• Calculated bone strength of the hip by Finite Element Modeling
• Whole body and regional BMD by DXA
• Lower leg BMD by pQCT
• Serum markers of bone turnover
• Urine markers of bone turnover
Renal Stone Risk 
• Serum and urine renal stone parameters
• Abdominal ultrasound for renal stones
Conclusion
Current results support the hypothesis that adding an anti-
resorption agent will be beneficial for bone protection -- reducing 
remodeling rate, bone loss, and urinary Ca and protecting bone 
strength.
Need more data to:
• Clarify impact of bisphosphonate countermeasure on bone strength 
• Define compartmental bone loss (cortical vs. trabecular)
• Understand impact of changing exercise prescription on conclusions
• Improve precison, i.e., the predictive value for calculating    
benefit/risk for individual crewmembers
Results
Compared to previous ISS crewmembers (n=14) not taking alendronate, DXA measurements of the total hip BMD were significantly 
changed from -1.1 ± 0.5%/mo to 0.04 ± 0.3%/mo (p<0.01); QCT-determined trabecular BMD of the total hip was significantly changed 
from -2.3 ± 1.0%/mo to -0.3 ± 1.6%/mo (p<0.01).  Significance was calculated from a one-tailed t-test.  While these results are 
encouraging, the current n (4) is small, and the large SDs indicate that while the means are improved there is still high variability in 
individual response.
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